ACS Pharmacology & Translational Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 23, 2025
Skin
cancer
represents
a
major
health
concern
due
to
its
rising
incidence
and
limited
treatment
options.
Current
treatments
(surgery,
chemotherapy,
radiotherapy,
immunotherapy,
targeted
therapy)
often
entail
high
costs,
patient
inconvenience,
significant
adverse
effects,
therapeutic
efficacy.
The
search
for
novel
options
is
also
marked
by
the
capital
investment
extensive
development
involved
in
drug
discovery
process.
In
response
these
challenges,
repurposing
existing
drugs
topical
application
optimizing
their
delivery
through
nanotechnology
could
be
answer.
This
innovative
strategy
aims
combine
advantages
of
known
pharmacological
background
commonly
used
expedite
development,
with
nanosystem-based
formulations,
which
among
other
allow
improved
skin
permeation
retention
overall
higher
efficacy
safety.
present
review
provides
critical
analysis
repurposed
such
as
doxycycline,
itraconazole,
niclosamide,
simvastatin,
leflunomide,
metformin,
celecoxib,
formulated
into
different
nanosystems,
namely,
nanoemulsions
nanoemulgels,
nanodispersions,
solid
lipid
nanoparticles,
nanostructured
carriers,
polymeric
hybrid
lipid-polymer
electrospun
nanofibrous
scaffolds,
liposomes
liposomal
gels,
ethosomes
ethosomal
aspasomes,
outcomes
battle
against
cancer.
Enhanced
antitumor
effects
on
melanoma
nonmelanoma
research
models
are
highlighted,
some
nanoparticles
even
showing
intrinsic
anticancer
properties,
leading
synergistic
effects.
explored
findings
highly
evidence
potential
approaches
complement
currently
available
strategies
hope
that
might
one
day
reach
pharmaceutical
market.
Journal of drug targeting,
Год журнала:
2024,
Номер
unknown, С. 1 - 27
Опубликована: Ноя. 1, 2024
Since
its
emergence
shortly
after
the
discovery
of
penicillin,
antibiotic
resistance
has
escalated
dramatically,
posing
a
significant
health
threat
and
economic
burden.
Combating
resistance,
especially
in
Gram-negative
bacteria
(GNB)
drug-resistant
Mycobacterium
tuberculosis,
necessitates
innovative
research,
substantial
financial
investment,
global
cooperation
to
safeguard
public
develop
sustainable
solutions.
Drug
repositioning,
or
drug
repurposing,
involves
identifying
new
therapeutic
applications
for
existing
drugs,
utilizing
their
established
safety
profiles
pharmacological
data
swiftly
provide
effective
treatments
against
resistant
pathogens.
Several
including
otilonium
bromide,
penfluridol,
eltrombopag,
ibuprofen,
ceritinib,
have
demonstrated
potent
antibacterial
activity
multidrug-resistant
(MDR)
bacteria.
These
drugs
can
disrupt
biofilms,
damage
bacterial
membranes,
inhibit
growth.
Furthermore,
combination
repurposed
with
conventional
antibiotics
reduce
required
dosage
individual
mitigate
side
effects,
delay
development
making
it
promising
strategy
MDR
such
as
Staphylococcus
aureus,
Klebsiella
pneumoniae,
Pseudomonas
aeruginosa,
Escherichia
coli.
Despite
promise,
repurposing
faces
challenges
potential
off-target
toxicity,
regulatory
intellectual
property
issues,
necessitating
rigorous
evaluations
strategic
This
article
aims
explore
combat
examining
benefits,
challenges,
future
prospects.
We
address
legal,
economic,
practical
associated
highlight
successful
examples,
propose
solutions
enhance
efficacy
viability
this
approach
combating
infections.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(4), С. 3291 - 3291
Опубликована: Фев. 7, 2023
Lipid-lowering
therapies
are
widely
used
to
prevent
the
development
of
atherosclerotic
cardiovascular
disease
(ASCVD)
and
related
mortality
worldwide.
"Omics"
technologies
have
been
successfully
applied
in
recent
decades
investigate
mechanisms
action
these
drugs,
their
pleiotropic
effects,
side
aiming
identify
novel
targets
for
future
personalized
medicine
with
an
improvement
efficacy
safety
associated
treatment.
Pharmacometabolomics
is
a
branch
metabolomics
that
focused
on
study
drug
effects
metabolic
pathways
implicated
variation
response
treatment
considering
also
influences
from
specific
disease,
environment,
concomitant
pharmacological
therapies.
In
this
review,
we
summarized
most
significant
metabolomic
studies
lipid-lowering
therapies,
including
commonly
statins
fibrates
drugs
or
nutraceutical
approaches.
The
integration
pharmacometabolomics
data
information
obtained
other
"omics"
approaches
could
help
comprehension
biological
underlying
use
view
defining
precision
improve
reduce
European Journal of Pediatrics,
Год журнала:
2024,
Номер
183(9), С. 4057 - 4062
Опубликована: Июль 3, 2024
Abstract
Duchenne
muscular
dystrophy
is
life-limiting.
Cardiomyopathy,
which
mostly
ensues
in
the
second
decade
of
life,
main
cause
death.
Treatment
options
are
still
limited.
The
TAMDMD
(NCT03354039)
trial
assessed
motor
function,
muscle
strength
and
structure,
laboratory
biomarkers,
safety
79
ambulant
boys
with
genetically
confirmed
dystrophy,
6.5–12
years
age,
receiving
either
daily
tamoxifen
20
mg
or
placebo
for
48
weeks.
In
this
post-hoc
analysis,
available
echocardiographic
data
patients
recruited
at
one
study
centre
were
retrieved
compared
before
after
treatment.
Data
from
14
patients,
median
11
(interquartile
range,
IQR,
11–12)
age
was
available.
Baseline
demographic
characteristics
similar
participants
assigned
to
(
n
=
7)
7).
Left
ventricular
end-diastolic
diameter
group
(median
IQR)
39
(38–41)
mm
baseline
43
(38–44)
end,
while
it
44
(41–46)
41
(37–46)
treatment
group.
fractional
shortening
35%
(32–38%)
33%
(32–36%)
treatment,
34%
(33–34%)
(33–35%)
end.
No
signals
detected.
Conclusion
:
This
hypothesis-generating
analysis
suggests
that
over
weeks
well
tolerated
may
help
preserving
cardiac
structure
function
dystrophy.
Further
studies
justified.
ClinicalTrials.gov
Identifier
EudraCT
2017–004554–42,
NCT03354039
What
known:
•
(DMD)
Cardiomyopathy
life
Tamoxifen
reduced
fibrosis
mice
improved
cardiomyocyte
human-induced
pluripotent
stem
cell-derived
cardiomyocytes.
new:
among
boys,
treated
weeks,
well-tolerated.
A
visual
trend
left-ventricular
dimensions
better
systolic
preservation
generates
hypothesis
a
potential
beneficial
effect
DMD
cardiomyopathy.
ACS Pharmacology & Translational Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 23, 2025
Skin
cancer
represents
a
major
health
concern
due
to
its
rising
incidence
and
limited
treatment
options.
Current
treatments
(surgery,
chemotherapy,
radiotherapy,
immunotherapy,
targeted
therapy)
often
entail
high
costs,
patient
inconvenience,
significant
adverse
effects,
therapeutic
efficacy.
The
search
for
novel
options
is
also
marked
by
the
capital
investment
extensive
development
involved
in
drug
discovery
process.
In
response
these
challenges,
repurposing
existing
drugs
topical
application
optimizing
their
delivery
through
nanotechnology
could
be
answer.
This
innovative
strategy
aims
combine
advantages
of
known
pharmacological
background
commonly
used
expedite
development,
with
nanosystem-based
formulations,
which
among
other
allow
improved
skin
permeation
retention
overall
higher
efficacy
safety.
present
review
provides
critical
analysis
repurposed
such
as
doxycycline,
itraconazole,
niclosamide,
simvastatin,
leflunomide,
metformin,
celecoxib,
formulated
into
different
nanosystems,
namely,
nanoemulsions
nanoemulgels,
nanodispersions,
solid
lipid
nanoparticles,
nanostructured
carriers,
polymeric
hybrid
lipid-polymer
electrospun
nanofibrous
scaffolds,
liposomes
liposomal
gels,
ethosomes
ethosomal
aspasomes,
outcomes
battle
against
cancer.
Enhanced
antitumor
effects
on
melanoma
nonmelanoma
research
models
are
highlighted,
some
nanoparticles
even
showing
intrinsic
anticancer
properties,
leading
synergistic
effects.
explored
findings
highly
evidence
potential
approaches
complement
currently
available
strategies
hope
that
might
one
day
reach
pharmaceutical
market.
